Description
Composition
Each inhaled dose of ASMABRON® 25/125 contains: Salmeterol (as Hydroxynaphthoate) 25 mcg Fluticasone propionate 125 mcg Propellant HFA 134a. Excipient q.s.
Each inhaled dose of ASMABRON® 25/250 contains: Salmeterol (as Hydroxynaphthoate) 25 mcg Fluticasone propionate 250 mcg Propellant HFA 134a. Excipient q.s.
Therapeutic Action
Aerosol for oral inhalation. Bronchodilator and Glucocorticoid. Anti-inflammatory action at the bronchopulmonary level and long-acting bronchodilator.
Indications
Asmabron® is indicated for the regular treatment of reversible respiratory obstruction, including asthma in children and adults, where the use of a combination of a bronchodilator and an inhaled corticosteroid is appropriate. Prophylaxis and treatment of asthma. Preventive use in mild, moderate and severe persistent asthma.
Presentations
ASMABRON®25 / 125 (Salmeterol 25 mcg / Fluticasone Propionate 125 mcg): Dosing aerosol containing 120 doses.
ASMABRON®25 / 250 (Salmeterol 25 mcg / Fluticasone Propionate 250 mcg): Dosing spray containing 120 doses.
